Savara Inc. operates as an orphan lung disease company. Its lead product candidate includes Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis; and in Phase IIa development stage for treating nontuberculous mycobacterial lung infection. The company is also developing AeroVanc, an inhaled vancomycin that is in Phase III stage for the treatment of methicillin-resistant Staphylococcus aureus lung infection in individuals living with cystic fibrosis. Savara Inc. is headquartered in Austin, Texas.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [08/16/2019 11:07 PDT] Savara Inc. (NASDAQ:SVRA), Down By 100.00% ($2.30) From $2.300 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [08/09/2019 10:29 PDT] Savara Inc. (NASDAQ:SVRA), Down By 100.00% ($2.51) From $2.510 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [08/09/2019 08:07 PDT] SVRA Expected to Trade Down After Bearish Patterns Develop
• [08/06/2019 08:07 PDT] SVRA Expected to Trade Down After Bearish Patterns Develop
• [07/16/2019 07:55 PDT] SVRA Expected to Trade Up After Bullish Patterns Develop